CHPT
ChargePoint Holdings, Inc.
CHPT has the edge over LCID overall, supported by stronger modeled upside.
LCID
Lucid Group, Inc.
LCID has lower modeled downside risk, despite its lower overall score.
CHPT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Unavailable |
CHPT's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
LCID Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
LCID's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
CHPT PE Valuation
CHPT has no meaningful PE right now: it lost money over the past year.
LCID PE Valuation
LCID has no meaningful PE right now: it lost money over the past year.
CHPT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect CHPT's losses to shrink, with revenue growing.
LCID Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect LCID's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
CHPT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$7.26 | +$4.19 |
| Q2 2026 | -$8.76 | +$3.04 |
| Q1 2026 | -$9.41 | +$3.39 |
| Q4 2025 | -$10.08 | +$4.32 |
| Q3 2025 | -$11.45 | +$7.95 |
| Q2 2025 | -$11.80 | +$11.40 |
| Q1 2025 | -$12.80 | +$11.60 |
| Q4 2024 | -$14.40 | +$10.20 |
CHPT has the edge over LCID on earnings, with more consistent year-over-year improvement.
LCID Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$13.08 | -$2.57 |
| Q2 2026 | -$13.65 | -$2.35 |
| Q1 2026 | -$13.15 | -$1.25 |
| Q4 2025 | -$12.09 | +$0.41 |
| Q3 2025 | -$10.51 | +$2.49 |
| Q2 2025 | -$11.30 | +$0.40 |
| Q1 2025 | -$11.90 | +$0.40 |
| Q4 2024 | -$12.50 | +$1.10 |
LCID is still losing money, but less than at its worst: $13.08 per share over the past year, against $16.50 at its worst in mid-2023.
CHPT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $116.1M | +18% |
| Q2 2026 | $101.8M | +4.3% |
| Q1 2026 | $109.3M | +7.3% |
| Q4 2025 | $105.7M | +6.1% |
| Q3 2025 | $98.6M | -9.2% |
| Q2 2025 | $97.6M | -8.8% |
| Q1 2025 | $101.9M | -12% |
| Q4 2024 | $99.6M | -9.7% |
CHPT's revenue is recovering but still below its 2023 peak: $116M last quarter, up 18% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -29% | +31 points |
| Q2 2026 | -46% | +8.8 points |
| Q1 2026 | -48% | +5.5 points |
| Q4 2025 | -42% | +27 points |
| Q3 2025 | -60% | -2 points |
| Q2 2025 | -55% | +7.6 points |
| Q1 2025 | -54% | +26 points |
| Q4 2024 | -68% | +71 points |
CHPT has the edge over LCID on profitability, with a higher operating margin.
LCID Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $350.3M | +4.1% |
| Q2 2026 | $405.3M | +56% |
| Q1 2026 | $282.5M | +20% |
| Q4 2025 | $522.7M | +123% |
| Q3 2025 | $336.6M | +68% |
| Q2 2025 | $259.4M | +29% |
| Q1 2025 | $235M | +36% |
| Q4 2024 | $234.5M | +49% |
LCID has the edge over CHPT on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -245% | +35 points |
| Q2 2026 | -267% | +43 points |
| Q1 2026 | -350% | -56 points |
| Q4 2025 | -204% | +109 points |
| Q3 2025 | -280% | +105 points |
| Q2 2025 | -310% | +83 points |
| Q1 2025 | -294% | +128 points |
| Q4 2024 | -313% | +156 points |
LCID's operating margin was −245% last quarter, up 35 points from the same quarter a year ago, near the top of its range since 2020.
CHPT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$5.2M | +$2.3M |
| Q2 2026 | -$37.7M | -$3.7M |
| Q1 2026 | -$2M | +$2.6M |
| Q4 2025 | -$23.6M | +$9.8M |
| Q3 2025 | -$7.5M | +$47.5M |
| Q2 2025 | -$34M | +$32M |
| Q1 2025 | -$4.6M | +$41.6M |
| Q4 2024 | -$33.4M | +$68.3M |
CHPT has the edge over LCID on cash flow, with more consistent year-over-year improvement.
LCID Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1B | -$84.2M |
| Q2 2026 | -$1.5B | -$463.2M |
| Q1 2026 | -$1.4B | -$849M |
| Q4 2025 | -$1.2B | -$417.1M |
| Q3 2025 | -$955.5M | -$333M |
| Q2 2025 | -$1B | -$271.6M |
| Q1 2025 | -$589.9M | +$125.1M |
| Q4 2024 | -$824.8M | -$77.6M |
LCID has burned cash in almost every quarter: −$5.2B over the past year, against −$3.4B the year before.
CHPT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +6.9% | +1.7M shares |
| 1 year | +13% | +3.1M shares |
| 3 years | +48% | +8.5M shares |
| 5 years | +68% | +10.6M shares |
CHPT has the edge over LCID on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2019 | — |
LCID Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.3% | +12.5M shares |
| 1 year | +26% | +82.4M shares |
| 3 years | +73% | +166M shares |
LCID has 395M diluted shares, up 26% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | $2.2M |
| Q1 2020 | — |
CHPT Net Leverage
CHPT's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LCID Net Leverage
LCID's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
CHPT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 65.1 | Neutral |
| Stochastic | 84.4 | Overbought |
CHPT's weekly RSI is 65 (neutral) and its Stochastic is 84 (overbought).
LCID Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.9 | Neutral |
| Stochastic | 7.1 | Oversold |
LCID's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
CHPT PE vs Consumer Cyclical Sector
CHPT has no meaningful PE right now: it lost money over the past year.
LCID PE vs Consumer Cyclical Sector
LCID has no meaningful PE right now: it lost money over the past year.
CHPT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $9.32 | 29% above |
| 20 week MA | $7.81 | 54% above |
| 50 week MA | $7.08 | 70% above |
| 100 week MA | $10.4 | 16% above |
| 200 week MA | $49.3 | 76% below |
CHPT has the edge over LCID on trend strength, trading above more of its moving averages.
LCID Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.53 | 7.9% below |
| 20 week MA | $4.88 | 33% below |
| 50 week MA | $7.33 | 56% below |
| 100 week MA | $15.4 | 79% below |
| 200 week MA | $31.9 | 90% below |
LCID is in a downtrend: it's below all five of its weekly moving averages, and 90% below its 200-week average.
CHPT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $196.0 | $922.0 | +370% |
| 2021 | $922.0 | $381.0 | -59% |
| 2022 | $381.0 | $171.0 | -55% |
| 2023 | $171.0 | $46.8 | -73% |
| 2024 | $46.8 | $22.8 | -51% |
| 2025 | $22.8 | $7.08 | -69% |
| 2026 YTD | $7.08 | $12.1 | +70% |
CHPT has the edge over LCID on returns for 2026, with the stronger performance.
LCID Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $98.9 | $100.4 | +1.5% |
| 2021 | $100.4 | $376.4 | +275% |
| 2022 | $376.4 | $67.0 | -82% |
| 2023 | $67.0 | $42.1 | -37% |
| 2024 | $42.1 | $32.0 | -24% |
| 2025 | $32.0 | $11.4 | -64% |
| 2026 YTD | $11.4 | $3.25 | -72% |
LCID has finished four years in a row lower, and it's down 72% so far in 2026.